Merck & Co. AI Adoption Tracker
Last updated: August 9, 2026
Overview
Merck has positioned itself as a leader in pharmaceutical AI transformation through comprehensive deployment across its value chain[1]. The company has developed multiple AI initiatives including foundation models for drug discovery, generative AI platforms for clinical operations, and enterprise-wide adoption of AI tools. Merck's approach combines proprietary AI development with strategic partnerships, including collaborations with BenevolentAI and Exscientia worth over $1.2 billion[2]. The company has achieved significant operational improvements, including reducing clinical study report generation time from 2-3 weeks to 3-4 days and cutting drafting errors by 50%[3]. With over 25,000 employees using their internal AI platform myGPT Suite and more than 80% of the workforce utilizing their proprietary AI tools, Merck demonstrates enterprise-scale AI adoption[4].
AI Maturity Index
Radar Comparison
Peer Comparison: Merck & Co. vs healthcare
Based on 66 companies in sector
| Dimension | Merck & Co. | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 4.0 | 3.7 | +0.3 |
| Proficiency | 4.0 | 3.5 | +0.5 |
| Impact | 4.0 | 3.6 | +0.4 |
| Overall | 4.0 | 3.6 | +0.4 |
Key Metrics
AI Initiatives
KERMT Small Molecule Model
December 2025
AI model for small molecule drug discovery developed with Nvidia
Pretrained on over 11 million molecules and fine-tuned for ADMET property prediction, improving predictive performance and reducing computation time
AI-Powered Clinical Study Reports
June 2025
Generative AI solution for automating clinical study report creation
Platform leveraging large language models to expedite creation of first drafts of clinical study reports from 180 hours to 80 hours, reducing errors by 50% and timeline from 2-3 weeks to 3-4 days
TEDDY Foundation Model
2025
Large foundational model for biologics and large molecule development
AI model focused on oncology applications in the biologics space, used for target identification and drug discovery workflows
GPTeal Platform
2024
Proprietary generative AI platform providing secure access to large language models
Gated LLM interface allowing scientists to interact with ChatGPT, Llama, and Claude within secure corporate environment. Used by over 50,000 employees for routine tasks like drafting emails, summarizing documents, and composing regulatory text
myGPT Suite
2024
Enterprise AI platform developed in partnership with Langdock
Internal LLM-powered platform with over 25,000 users and 14,000+ monthly active users. Includes 3,000+ internal assistants created by employees
Frequently Asked Questions
Merck has invested over $1.2 billion in AI partnerships, including $674 million with Exscientia and $594 million with BenevolentAI, plus additional undisclosed internal investments.
Merck uses AI for drug target identification, molecular design, clinical trial optimization, manufacturing automation, supply chain protection, and regulatory document generation.
Over 25,000 employees use the myGPT Suite platform, with more than 80% of the workforce utilizing Merck's proprietary AI tools for various tasks.
Merck has reduced clinical study report generation from 2-3 weeks to 3-4 days, cut drafting errors by 50%, and achieved significant productivity improvements across multiple business units.
Merck has established AI ethics and compliance principles, implements human oversight requirements, uses secure enterprise platforms, and maintains strict governance frameworks for AI deployment.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| GPTeal | Internally developed | Secure access to ChatGPT, Llama, and Claude for scientific workflows |
| myGPT Suite | Developed with Langdock | Enterprise-wide AI platform for productivity and workflow automation |
| Celonis | Celonis | Process mining and intelligence to inform AI strategy and measure process improvements |
Sources
5 ways we're transforming artificial intelligence into impact
Artificial Intelligence at Merck - Two Use Cases
Merck Expands Innovative Internal Generative AI Solutions
How 25,000 Merck employees started using GenAI in <6 months
GPTeal: Merck's Generative AI Strategy for Pharma R&D
AI Partnerships in Healthcare
Merck and Nvidia team up on new drug discovery model
For Merck, AI Puts Humans In the Right Room
Merck & Co., Inc. Form 10-K
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.